Quanterix (NASDAQ:QTRX) Releases Earnings Results, Beats Estimates By $0.12 EPS

by · The Cerbat Gem

Quanterix (NASDAQ:QTRX – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.12, Zacks reports. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%.The company had revenue of $35.90 million for the quarter, compared to analysts’ expectations of $36.84 million.

Here are the key takeaways from Quanterix’s conference call:

  • Quanterix is increasing investment in its Alzheimer’s diagnostics business, hiring a new diagnostics leader, expanding lab infrastructure, pursuing FDA clearance for LucentAD Complete in H2 2026, and announcing a partnership with Tempus AI to integrate ordering into select EHRs.
  • The company reported $36.4 million in Q1 revenue (reported +20% YoY but organic revenue declined 21%), with instrumentation sales softer than expected, 16 Simoa and 11 spatial placements, and pharma revenue down ~33% while academia represented ~65% of Q1 sales.
  • Management says it has delivered the $85 million of annualized Akoya cost synergies, maintained >50% non-GAAP gross margin, narrowed adjusted EBITDA loss to $9.8 million, and ended the quarter with $102.6 million in cash and no debt while targeting cash-flow breakeven in the second half of 2026.
  • Leadership is shifting from integration to growth and has launched commercial effectiveness initiatives—adding lead-generation reps, market development leaders, leveraging Thermo Fisher distribution, and prioritizing an HD‑X upgrade (with an IVD filing planned in 2027) and Simoa1 early-access feedback to drive second-half revenue.
  • The company changed its accounting classification for shipping and handling into cost of goods sold (affecting GAAP gross margin presentation but not non-GAAP margins) and reiterated full‑year 2026 revenue guidance of $169 million–$174 million.

Quanterix Stock Performance

NASDAQ:QTRX traded up $0.08 on Friday, hitting $2.83. The stock had a trading volume of 2,359,120 shares, compared to its average volume of 1,158,731. Quanterix has a 1 year low of $2.56 and a 1 year high of $8.77. The firm’s fifty day simple moving average is $4.11 and its two-hundred day simple moving average is $5.60. The stock has a market cap of $133.32 million, a P/E ratio of -1.20 and a beta of 1.15.

Institutional Trading of Quanterix

A number of hedge funds have recently bought and sold shares of QTRX. Virtu Financial LLC purchased a new stake in shares of Quanterix during the 4th quarter valued at $131,000. Invesco Ltd. boosted its holdings in shares of Quanterix by 14.7% in the 4th quarter. Invesco Ltd. now owns 113,200 shares of the company’s stock worth $720,000 after buying an additional 14,508 shares during the last quarter. XTX Topco Ltd grew its position in Quanterix by 555.1% during the fourth quarter. XTX Topco Ltd now owns 74,093 shares of the company’s stock valued at $471,000 after buying an additional 62,783 shares during the period. Tudor Investment Corp ET AL purchased a new stake in Quanterix during the fourth quarter worth about $1,079,000. Finally, Quadrature Capital Ltd purchased a new stake in Quanterix during the fourth quarter worth about $138,000. 86.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on QTRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quanterix in a research note on Tuesday, April 21st. TD Cowen lowered their target price on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating on the stock in a report on Thursday. Wall Street Zen downgraded Quanterix from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Finally, Canaccord Genuity Group dropped their target price on Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Quanterix has a consensus rating of “Reduce” and a consensus price target of $4.00.

Get Our Latest Research Report on Quanterix

Quanterix Company Profile

(Get Free Report)

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

Read More